Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Saved in:
| Title: | Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials. |
|---|---|
| Authors: | Armstrong, April W.1 (AUTHOR), Augustin, Matthias2 (AUTHOR), Beaumont, Jennifer L.3 (AUTHOR), Pham, Tan P.3 (AUTHOR), Hudgens, Stacie3 (AUTHOR), Gordon, Kenneth B.4 (AUTHOR), Zhuo, Joe5 (AUTHOR) joe.zhuo@bms.com, Becker, Brandon5 (AUTHOR), Zhong, Yichen5 (AUTHOR), Kisa, Renata M.5 (AUTHOR), Banerjee, Subhashis5 (AUTHOR), Papp, Kim A.6,7 (AUTHOR) |
| Source: | Dermatology & Therapy. Apr2025, Vol. 15 Issue 4, p1037-1044. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
